Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.64% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
CUE · Dec 31, 2025
Cue Biopharma, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-108287General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-78.96% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
195.75% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-96.67% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
137.42% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
17.27% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History29 statesHistory building
Sep 30, 20216/6 normalizedLevel 3Dec 31, 20216/6 normalizedLevel 3Mar 31, 20226/7 normalizedLevel 3Jun 30, 20226/7 normalizedLevel 3Sep 30, 20226/7 normalizedLevel 3Dec 31, 20226/7 normalizedLevel 3Mar 31, 20236/7 normalizedLevel 3Jun 30, 20236/7 normalizedLevel 3Sep 30, 20236/7 normalizedLevel 3Dec 31, 20236/7 normalizedLevel 3Mar 31, 20247/7 normalizedLevel 3Jun 30, 20247/7 normalizedLevel 3Sep 30, 20247/7 normalizedLevel 3Dec 31, 20246/6 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/6 normalizedLevel 3Dec 31, 20256/6 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 0.00%
- Current
- 0.64%
- Delta
- 0.64%
- Previous
- -419.92%
- Current
- -78.96%
- Delta
- 340.96%
- Previous
- -35.58%
- Current
- 195.75%
- Delta
- 231.33%
- Previous
- -353.42%
- Current
- -96.67%
- Delta
- 256.75%
- Previous
- 221.22%
- Current
- 137.42%
- Delta
- -83.80%
- Previous
- 71.34%
- Current
- 17.27%
- Delta
- -54.06%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · CUE Fundamental State →Has State · Cue Biopharma, Inc. →Transitioned To · CUE Fundamental State →Transitioned To · CUE CAPEX_INTENSITY_INCREASED →Transitioned To · CUE CASH_GENERATION_INCREASED →Transitioned To · CUE GROWTH_INCREASED →Transitioned To · CUE PROFITABILITY_INCREASED →Transitioned To · CUE R_AND_D_INTENSITY_DECREASED →Transitioned To · CUE SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.